Key Takeaways
- Derivatives mix hits 50% target, margins recover: Revenue from derivatives and specialty crossed 52% in Q4, and EBITDA margin climbed to 30% from 21% in Q1, driving a 25% full-year margin.
- Volume-led recovery, but realisations still weak: FY24 volume grew 15% on new project ramp-ups, yet revenue fell 12% as realisations dropped 12–45% across divisions. Management believes realisations have bottomed.
- Debt has peaked, cash flows to drive deleveraging: Management stated debt peaked this year and will only come down over the next six months as cash flows arrive, with preferential holding-company debt repaid first.
- New capacity to drive FY25 volume growth of ~15%: CPVC resin (+45,000 tons), Chlorotoluene, and CPVC compound projects all commission through FY25, with full optimisation expected only in FY26.
- What to watch next quarter: Whether realisations actually improve from the claimed bottom, the pace of Chlorotoluene commissioning and customer qualification, and the size and nature of the new project announcement promised in a couple of months.
Margin Recovery & Sustainability
- Sequential margin climb: EBITDA margin improved every quarter from 21% in Q1 FY24 to 30% in Q4, driven by higher volumes, better absorption, and improved spreads as raw material prices cooled in H2.
- Raw material tailwind: A combination of raw material costs cooled in the second half of FY24 versus the first half, contributing to the margin uplift, though management declined to quantify the decline or name specific materials.
- Integration and utilisation gains: New products commissioned in FY23 were not running at optimum levels early in FY24; as capacity utilisation improved through the year, margins benefited from operating leverage.
- Power cost advantage: Epigral realised a 6–7 month gain in power cost from its 18.34 MW wind-solar hybrid project, and 100% of power needs are met from captive sources, insulating the company where power is 50–55% of caustic cost.
- FY25 margin guide: Management expects margins around 25% for the full year and believes that level is sustainable, with upside if all products stand in a strong position.
Kotecha: "we believe that 25% in the range would be something which is definitely sustainable."
Derivatives & Specialty Mix Shift
- 52% achieved in Q4: Derivatives and specialty contribution crossed 50% of revenue in Q4 FY24 (45% for the full year), up from 30% in FY23, fulfilling a stated target and making the business more resilient through a tough cycle.
- Next target is 70-30: Management aims for 70% derivatives and specialty, 30% Chlor-Alkali by FY27, when all current expansions reach commissioning. In FY25, the derivatives mix is expected to reach 55–60%.
- Product selection logic: The company targets products that are first-time-in-India, where the market is growing in double digits, and that strengthen its integrated complex. Chlorotoluene, with 10–15 import-substitute products in phase one, fits this template.
Patel: "next target we have kept it is 70-30. So, 70% will be derivatives and specialty and 30% will be in the Chlor-Alkali business."
Capacity Expansion & Ramp-Up Timelines
| Project | Capacity / Scope | Commissioning | Optimum Utilisation |
|---|---|---|---|
| CPVC resin (additional) | 45,000 tons | Commissioned; ramp in progress | Q4 FY25 (4–5 months to optimum) |
| Chlorotoluene value chain | 3 blocks, 10–15 products (phase 1) | Block-by-block over next 3–4 months; all by end-Q2 FY25 | End-Q4 FY25 (~60% utilisation by Q4) |
| CPVC compound facility | Not quantified separately | Q1 and Q2 FY25 | Part of integrated CPVC chain |
| New project (unannounced) | ~INR250 crores capex | Announcement in a couple of months | Not stated |
- FY26 as the full-utilisation year: Management expects FY26 to be the year when all products run at optimum, with asset turnover staying in the 1.2–1.3x range even after these plants are commissioned.
- Future capex direction: Investment focus remains on downstream chemicals and value-added derivatives from what is currently produced, reinforcing the 70-30 mix target.
Demand & Realisation Outlook
- Demand recovering, realisations lagging: Demand has improved sequentially every quarter from Q2 FY24, but realisations remain subdued. Management believes realisations are at the bottom and likely to improve from FY25 onward.
- Volume growth guidance: The company is targeting around 15% volume growth in FY25, driven by new capacity ramp-ups across CPVC, Chlorotoluene, and CPVC compounds.
- Chlor-Alkali muted: No big jump expected in Chlor-Alkali in FY25; domestic demand has picked up but the export market has not recovered to pre-COVID levels, with Europe and the US still reviving.
- ECH demand doubling expected: Epichlorohydrin demand is expected to almost double from current levels in the next five years, driven by renewable energy (windmill), adhesives, and automotive, all growing double-digit in India. A second bulk shipment to Europe was completed this month, and a large US contract is targeted for H2 FY25.
- CPVC pricing cautious: CPVC prices may stay flat or improve slightly in FY25, but management said it is difficult to commit to any number.
Patel: "we are expecting very high growth in next coming five years or coming decade for this particular product... at least the demand will pick up almost double from here in next five years."
Competitive Dynamics & Industry Context
- Caustic soda balance: India became a net importer of caustic because rising alumina capacity in eastern India created additional demand, while exports fell due to a poor global scenario.
- Adani's entry: Adani's new Chlor-Alkali plant is positive for PVC (India is a net importer) but will put short-term pressure on caustic. Management expects alumina capacity growth to absorb the additional caustic supply within a couple of years, and notes Adani's capacity will come in phases.
- Middle East tension: As a net importer of chemicals, India benefits from any tension outside the country, which supports domestic manufacturing.
Patel: "in terms of caustic, there will be pressure a little bit, but we believe that going forward, our alumina capacity in India is growing... the demand will match probably in a couple of years. So, the pressure will be there on the caustic side, but not for a long term, for a short term."
Balance Sheet & Capital Allocation
- Debt peaked: Management stated debt has peaked in the current year and, with cash flows arriving, will only come down over the next six months, returning to earlier levels well under 2x and eventually much lower.
- Repayment priority: Preferential debt from the holding company (INR95 crores) will be repaid first as a matter of good corporate governance.
- Capex vs. deleveraging balance: Surplus cash flows after capex in FY25 and FY26 will be directed toward debt reduction, but management will always balance growth capex with deleveraging rather than prioritise one exclusively.
- Interest cost tailwind: Q4 interest cost was low versus Q4 last year due to a positive mark-to-market provision and debt repayment.
- Receivables increase explained: Trade receivables rose ~7.5% despite a 7–8% revenue decline because newer products (CPVC, Chlorotoluene) carry longer credit periods than legacy businesses.
Jain: "the kind of debt that we have, it looks like that it has peaked out in this current year, maybe in the next six months. Thereafter, with the cash flows coming in, it will only be coming down."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Volume growth | Around 15% volume growth | FY25 |
| EBITDA margin | Around 25% range, sustainable | FY25 |
| Derivatives revenue mix | 55–60% of revenue | FY25 |
| Derivatives revenue mix | 70% derivatives and specialty, 30% Chlor-Alkali | By FY27 |
| CPVC resin additional capacity | Reach optimum utilisation | Q4 FY25 |
| Chlorotoluene project | All blocks commissioned; product movement starts | End-Q2 FY25 for commissioning; Q4 FY25 for product movement |
| Chlorotoluene utilisation | Reach ~60% utilisation | End-Q4 FY25 |
| All products at optimum | Full utilisation across all products | FY26 |
| Debt reduction | Debt to come down from peak; preferential holding-company debt repaid first | Next six months |
| New project announcement | ~INR250 crores capex deployed toward new projects | Announcement in a couple of months |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue | ₹525 cr, +11% QoQ and -7% YoY |
| EBITDA | ₹155 cr, +27% QoQ |
| EBITDA margin | 30%, vs 26% in Q3 FY24 and 28% in Q4 FY23 |
| PAT | ₹77 cr, +55% QoQ |
| PAT margin | 15%, vs 10% in Q3 FY24 |
| FY24 revenue | ₹1,929 cr, -12% YoY |
| FY24 EBITDA margin | 25% |
| FY24 PAT | ₹196 cr, margin of 10% |
| FY24 ROCE | 17% including CWIP, 21% excluding CWIP, 24% on annualized EBIT |
| Sales volume growth | +9% YoY and +4% QoQ |
| FY24 volume growth | +15% |
| Capacity utilization | 83%, vs 81% in Q3 FY24 |
| Derivative and specialty revenue share | 52%, vs 44% in Q3 FY24 and 38% in Q4 FY23 |
| Net debt | ₹960 cr as of 31st Mar 2024, +₹98 cr YoY |
| FY24 capex | ₹405 cr |
| ECU | ~29,000 in Q4, ~28,500 for full FY24 |
| Epichlorohydrin utilization | ~60%, vs ~55% in Q3 FY24 |
| Chlorine captive consumption | 65% of total production |
| CPVC resin price | ~₹1,30,000 per ton |
| Dividend | ₹5 per share (50% on face value of ₹10) |